|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Tom_Barnes
|
|
gptkbp:collaboratedWith
|
gptkb:Merck_&_Co.
|
|
gptkbp:collaborationValue
|
$3.5 billion
|
|
gptkbp:focusesOn
|
circular RNA therapeutics
|
|
gptkbp:foundedIn
|
2019
|
|
gptkbp:founder
|
gptkb:Daniel_Anderson
gptkb:Tom_Barnes
Adrienne Elizondo
|
|
gptkbp:fundedBy
|
$221 million Series B
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Orna Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:investor
|
gptkb:Avidity_Partners
gptkb:EcoR1_Capital
gptkb:Invus
gptkb:Omega_Funds
gptkb:Pivotal_bioVenture_Partners
gptkb:RA_Capital_Management
gptkb:RTW_Investments
gptkb:Redmile_Group
gptkb:Polaris_Partners
gptkb:Morningside_Ventures
gptkb:Casdin_Capital
gptkb:Qiming_Venture_Partners_USA
gptkb:Bain_Capital_Life_Sciences
gptkb:Fidelity_Management_&_Research_Company
gptkb:Gilead_Sciences
gptkb:Samsara_BioCapital
gptkb:Sofinnova_Investments
gptkb:T._Rowe_Price
gptkb:Viking_Global_Investors
gptkb:Wellington_Management
gptkb:Cormorant_Asset_Management
gptkb:Janus_Henderson_Investors
gptkb:Surveyor_Capital
gptkb:The_Column_Group
gptkb:Amgen_Ventures
gptkb:Bristol_Myers_Squibb
GV (formerly Google Ventures)
Acorn Bioventures
Arkin Bio Ventures
BioImpact Capital
Ponoi Capital
|
|
gptkbp:technology
|
oRNA circular RNA platform
|
|
gptkbp:therapeuticArea
|
immunology
oncology
genetic diseases
|
|
gptkbp:website
|
https://www.ornatx.com/
|
|
gptkbp:bfsParent
|
gptkb:Fine_Structure_Ventures
|
|
gptkbp:bfsLayer
|
7
|